BTIS
CRBP icon

BB&T Investment Services’s Corbus Pharmaceuticals CRBP Stock Holding History

BB&T Investment Services’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$32K Buy
151
+24
+19% +$5.14K 0.01% 664
2017
Q3 		$27K Buy
+127
New +$24.8K 0.01% 648

Other funds holding CRBP

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BB&T Investment Services's CRBP Position: Q4 2017 in Review

BB&T Investment Services increased its Corbus Pharmaceuticals (CRBP) stake by 19% in Q4 2017, buying an estimated $5.14K and bringing the position to 151 shares worth $32K. The position accounts for 0.01% of the portfolio, ranked #664.

BB&T Investment Services first reported a position in CRBP in Q3 2017 and has held it in 2 quarters since. 88 funds tracked by Wall St. Rank hold CRBP as of Q4 2017.

  • BB&T Investment Services held 151 shares of Corbus Pharmaceuticals worth $32K as of Q4 2017.
  • BB&T Investment Services bought 24 Corbus Pharmaceuticals shares in Q4 2017, an estimated $5.14K.
  • Corbus Pharmaceuticals made up 0.01% of BB&T Investment Services's portfolio in Q4 2017, its #664 holding.
  • BB&T Investment Services first reported a position in Corbus Pharmaceuticals in Q3 2017 and has held it in 2 quarters since.
  • 88 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2017.

Based on BB&T Investment Services's 13F filing for Q4 2017, filed 15 Feb 2018.